RayKnowChina Research Map
Shortlist0

GuangzhouSun Yat-sen University

First Affiliated Hospital of Sun Yat-sen University

中山大学附属第一医院

Listed for 38 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at First Affiliated Hospital of Sun Yat-sen University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌14 papers led3 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌20 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌219 papers led6 open trials led
  4. Stomach cancer胃癌52 papers led
  5. Hepatoblastoma肝母细胞瘤5 papers led
  6. Retinoblastoma视网膜母细胞瘤1 paper led
  7. Chordoma脊索瘤0 papers led
  8. Osteosarcoma骨肉瘤33 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤9 papers led2 open trials led
  10. Neuroblastoma神经母细胞瘤0 papers led
  11. Ewing sarcoma尤文肉瘤1 paper led
  12. Multiple myeloma多发性骨髓瘤18 papers led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
  14. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  15. Beta thalassaemiaβ 地中海贫血5 papers led
  16. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  17. Myasthenia gravis重症肌无力28 papers led
  18. Moyamoya disease烟雾病4 papers led
  19. Wilson disease肝豆状核变性(Wilson 病)6 papers led
  20. Biliary atresia胆道闭锁12 papers led
  21. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  22. Takayasu arteritis大动脉炎0 papers led
  23. Hepatic echinococcosis肝包虫病1 paper led
  24. Idiopathic pulmonary fibrosis特发性肺纤维化9 papers led
  25. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  26. Spinal muscular atrophy脊髓性肌萎缩症4 papers led
  27. Fabry disease法布雷病0 papers led
  28. Pompe disease庞贝病0 papers led
  29. Duchenne muscular dystrophy杜氏肌营养不良5 papers led
  30. Behçet disease白塞病4 papers led
  31. Alport syndromeAlport 综合征0 papers led
  32. IgA nephropathyIgA 肾病22 papers led2 open trials led
  33. Gaucher disease戈谢病0 papers led
  34. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  35. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  36. Hirschsprung disease先天性巨结肠1 paper led
  37. Hereditary angioedema遗传性血管性水肿0 papers led
  38. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Aplastic anaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Lymphangioleiomyomatosis, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 14 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
14
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 4420232024: 1120242025: 332025

23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05860868

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  2. Recruiting
    ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-09
    Registry
    NCT05062005

    Age 18 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  3. Recruiting
    To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2020-06
    Registry
    NCT04547673

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou

  4. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  6. Recruiting
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04778956

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan

  7. Recruiting
    Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
    Phase
    N/A
    Started
    2017-10
    Registry
    NCT03353467

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryRadiation oncologyPathology / laboratory medicine
Papers it led14
  1. Nasopharyngeal necrosis following intensity-modulated radiation therapy of primary nasopharyngeal carcinoma-incidence rate and predictors of risk.2025BMC cancerFree full text
  2. Survival Outcomes Associated With the Size of Opioid Prescriptions in the Management of Chronic Pain Related to Advanced Nasopharyngeal Carcinoma.2025Ear, nose, & throat journal
  3. Transcriptomic profiling reveals mechanism, therapeutic potential, and prognostic value of cancer stemness characteristic in nasopharyngeal carcinoma.2025Functional & integrative genomics
  4. Development and validation of a nomogram to predicting the efficacy of PD-1/PD-L1 inhibitors in patients with nasopharyngeal carcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  5. The map of bone metastasis in nasopharyngeal carcinoma: A real-world study.2023Cancer medicineFree full text
  6. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.2023Cancer medicineFree full text
  7. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?2023Cancer medicineFree full text
  8. DNAJA4 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma via PSMD2-mediated MYH9 degradation.2023Cell death & diseaseFree full text
  9. Cisplatin-based concurrent chemoradiotherapy improved the survival of locoregionally advanced nasopharyngeal carcinoma after induction chemotherapy by reducing early treatment failure.2022BMC cancerFree full text
  10. Distinctive microbiota of delayed healing of oral mucositis after radiotherapy of nasopharyngeal carcinoma.2022Frontiers in cellular and infection microbiologyFree full text
  11. N7-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma.2022Oncogene
  12. Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.2021Oral oncology
  13. Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma - Authors' reply.2021The Lancet. Oncology
  14. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.2021The Lancet. OncologyRCT
Chinese-language papers (not in the count)5
  1. [Deep learning-based endoscopic diagnosis of nasopharyngeal carcinoma: model development and cloud deployment].2025Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [Efficacy of endoscopic surgical management for recurrent nasopharyngeal carcinoma].2024Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
  3. [The current state and future prospect of surgical treatment for nasopharyngeal carcinoma].2023Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  4. [Cost-effectiveness of endoscopic nasopharyngectomy in locally recurrent rT1-rT3 nasopharyngeal carcinoma: a study based on Markov model].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgeryRCT
  5. [Application of artificial intelligence in nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status13
  1. Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05860868Lead sponsorPhase 3Start 2023-05
  2. ICCRT vs. CRT for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05062005Lead sponsorPhase 3Start 2021-09
  3. To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal CarcinomaRecruitingNCT04547673Lead sponsorStart 2020-06
  4. Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies DetectionActive, not recruitingNCT06763289Lead sponsorStart 2024-12
  5. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  6. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  7. Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT04778956Study sitePhase 3Start 2021-03
  8. Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma PatientsRecruitingNCT03353467Study siteN/AStart 2017-10
  9. A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian CancerStatus unknownNCT06232863Study sitePhase 1Start 2023-01
  10. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  11. A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal NecrosisStatus unknownNCT05228093Study siteN/AStart 2021-11
  12. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
  13. A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal CarcinomaStatus unknownNCT02512315Study sitePhase 3Start 2015-08
More papers found outside PubMed (not counted)26
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  2. Enhanced sensitivity of nasopharyngeal carcinoma cells to cisplatin by triptolide: in vitro analysis of synergistic effects and mechanisms2025Pharmaciaarticle
  3. Hypoxia-induced USP22 contributes to tumor stemness and chemoresistance in nasopharyngeal carcinoma via stabilizing HIF-1α2025Molecular & Cellular Toxicologyarticle
  4. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncologyconference-abstract
  5. Differential sensitivities of primary tumor and lymph nodes to induction chemotherapy and definitive radiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  6. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  7. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncologyconference-abstract
  8. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  9. The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.2024Journal of Clinical Oncologyconference-abstract
  10. Additional file 1 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  11. Additional file 2 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  12. Additional file 3 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  13. Additional file 4 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  14. Additional file 5 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  15. Additional file 6 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  16. Additional file 7 of High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal carcinoma after radiotherapy2023Figsharedataset
  17. Data from EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation2023Venue not listedother
  18. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncologyconference-abstract
  19. 221O Induction chemotherapy regimen of docetaxel plus cisplatin vs docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of a phase III multi2022Annals of Oncologyarticle
  20. Cancer stem-like cells of nasopharyngeal carcinoma express CXCR4 and display highly invasive activity2022Research Squarepreprint
  21. Multidisciplinary Team Role in Cochlear Implantation after Radiotherapy and Chemotherapy in Nasopharyngeal Carcinoma Patients2022Venue not listedpreprint
  22. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncologyconference-abstract
  23. Application of Hypoxia-Driven Dual-Reporter Model to Explore the Effect of Hypoxia on Radiosensitivity of Human Nasopharyngeal Carcinoma Cells2021International Journal of Radiation Oncology*Biology*Physicsarticle
  24. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset
  25. Metastasis of nasopharyngeal carcinoma: What we know and do not know2021Visualized Cancer Medicinearticle
  26. Multimodality Management for Locally Advanced Nasopharyngeal Cancer2021Practical guides in radiation oncologybook-chapter

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 20 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
20
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 7720222023: 2220232024: 5520242025: 332025

11 hospitals in Guangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07863141

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyImaging & AI
Departments in papersRadiology / nuclear medicineRadiation oncologyMedical oncologyENT / head & neck surgery
Papers it led20
  1. 18F-FDG PET/CT and contrast-enhanced CT evaluation of lymph node status after neoadjuvant immunochemotherapy in patients with esophageal squamous cell carcinoma.2026European journal of nuclear medicine and molecular imaging
  2. TFAP2A-mediated Transcriptional Activation of ELMO1 Inhibits Ferroptosis and Promotes Esophageal Squamous Cell Carcinoma Progression.2026Molecular biotechnologyFree full text
  3. PCIF1 drives oesophageal squamous cell carcinoma progression via m6Am-mediated suppression of MTF2 translation.2025Clinical and translational medicineFree full text
  4. TP53-centric ctDNA complements PET/CT for non-invasive assessment of pathological complete response and survival after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a prospective cohort study.2025International journal of surgery (London, England)Free full text
  5. Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial.2025Nature communicationsFree full text
  6. Computed Tomography-Based Intratumor Heterogeneity Predicts Response to Immunotherapy Plus Chemotherapy in Esophageal Squamous Cell Carcinoma.2024Academic radiology
  7. Integrating bulk and single-cell sequencing data to construct a Scissor+ dendritic cells prognostic model for predicting prognosis and immune responses in ESCC.2024Cancer immunology, immunotherapy : CIIFree full text
  8. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.2024Cancer immunology, immunotherapy : CIIFree full text
  9. CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs.2024Journal for immunotherapy of cancerFree full text
  10. SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma.2024Thoracic cancerFree full text
  11. N7-methylguanosine (m7G) tRNA modification: a novel autophagy modulator in cancer.2023AutophagyFree full text
  12. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.2023European journal of cancer (Oxford, England : 1990)
  13. Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration.2022BMC bioinformaticsFree full text
  14. Clinical significance and outcomes of bilateral and unilateral recurrent laryngeal nerve lymph node dissection in esophageal squamous cell carcinoma: A large-scale retrospective cohort study.2022Cancer medicineFree full text
  15. The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma.2022European journal of nuclear medicine and molecular imaging
  16. miR-204-5p inhibits cell proliferation and induces cell apoptosis in esophageal squamous cell carcinoma by regulating Nestin.2022International journal of medical sciencesFree full text
  17. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.2022Journal for immunotherapy of cancerFree full text
  18. N7-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis.2022Nature communicationsFree full text
  19. Overexpression of GNA13 correlates with poor prognosis in esophageal squamous cell carcinoma after esophagectomy.2022The International journal of biological markers
  20. Endobronchial Ultrasound Improves Evaluation of Recurrent Laryngeal Nerve Lymph Nodes in Esophageal Squamous Cell Carcinoma Patients.2021Annals of surgical oncology
All its trials on ClinicalTrials.gov, any status4
  1. A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)RecruitingNCT07863141Lead (inferred)Phase 2Start 2026-10
  2. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  3. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  4. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)21
  1. LBA82 Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, phase II trial (EC-CRT-002)2025Annals of Oncologyconference-abstract
  2. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  3. 1440P Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial2024Annals of Oncologyarticle
  4. Abstract 5173: TRAIL expression in tumor cells predicts and drives poor response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  5. Abstract 6412: Combination of liquid biopsy and PET/CT enhances prediction of pathological response to neoadjuvant immunochemotherapy in patients with esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  6. Current advances on single or multi-omics analysis of esophageal cancer2024Advancements in Life Sciencesarticle
  7. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  8. Identification lymph node metastasis in esophageal squamous cell carcinoma using whole slide images and a hybrid network of multiple instance and transfer learning2023Biomedical Signal Processing and Controlarticle
  9. Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase Ⅱ trial.2023Journal of Clinical Oncologyconference-abstract
  10. Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase 2 trial.2023Journal of Clinical Oncologyconference-abstract
  11. 359. INTRATUMORAL MICROBIOME IMPACTS IMMUNE INFILTRATES IN TUMOR MICROENVIRONMENT AND PREDICTS PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS2022Diseases of the Esophagusarticle
  12. 479. THE ROLE OF PET/CT IN PREDICTING THE PATHOLOGICAL RESPONSE TO NEOADJUVANT IMMUNOCHEMOTHERAPY FOR RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  13. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  14. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  15. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  16. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  17. Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.2022Journal of Clinical Oncologyconference-abstract
  18. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figsharedataset
  19. Induction Anti-PD-1 Immunotherapy plus Chemotherapy Followed by Definitive Chemoradiation Therapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Real-World Retrospective Study2022International Journal of Radiation Oncology*Biology*Physicsarticle
  20. Neoadjuvant PD-1 blockade in combination with chemotherapy for patients with resectable esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract
  21. Predicting Response to Immunotherapy Plus Chemotherapy in Patients with Esophageal Squamous Cell Carcinoma Using Non-Invasive Radiomic Biomarkers2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 219 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.5%.

Papers led
219
2021–2025
Trials led
29
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 353520212022: 464620222023: 454520232024: 404020242025: 47472025

14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07487662

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  2. Recruiting
    DEB-TACE vs cTACE in HCC After TIPS
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07322848

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  3. Recruiting
    Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT06788353

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  4. Recruiting
    Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
    Phase
    Phase 2
    Started
    2020-12
    Registry
    NCT04615143

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  5. Not yet recruiting
    SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06739317

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  6. Not yet recruiting
    SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
    Phase
    Phase 3
    Started
    2023-03
    Registry
    NCT05718232

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  7. Recruiting
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
    Phase
    Phase 1
    Started
    2017-07
    Registry
    NCT03198546

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou

  8. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiation oncology
Papers it led219
  1. The role of liver stiffness measurement in predicting Long-term liver function after partial hepatectomy.2026Abdominal radiology (New York)
  2. Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.2026Alimentary pharmacology & therapeutics
  3. Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma.2026International journal of biological macromolecules
  4. Deep learning model integrating contrast-enhanced ultrasound spatiotemporal imaging with clinical data for the differential diagnosis between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.2026La Radiologia medica
  5. METTL5 promotes fatty acid metabolism by modulating peroxisome to induce hepatocellular carcinoma recurrence after thermal ablation.2026Molecular therapy : the journal of the American Society of Gene Therapy
  6. Deciphering the mechanism of aristolochic acid I-driven hepatocellular carcinoma through integrated network toxicology and bioinformatics.2026Naunyn-Schmiedeberg's archives of pharmacologyFree full text
  7. Explainable Fusion Model for Predicting Postoperative Early Recurrence in Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI Habitat Imaging.2025Academic radiology
  8. An Accurate Model for Microvascular Invasion Prediction in Solitary Hepatocellular Carcinoma ≤5 cm Based on CEUS and EOB-MRI: A Retrospective Study with External Validation.2025Academic radiology
  9. Identification of a postoperative survival scoring index for adult liver transplantation.2025Annals of medicineFree full text
  10. Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma.2025Apoptosis : an international journal on programmed cell deathFree full text
  11. Harnessing PD-1-overexpressing macrophage membrane for preparation of lenvatinib-loaded vesicles to boost immunotherapy against HCC recurrence after radiofrequency ablation.2025Biomaterials
  12. Unveiling the oncogenic role of lncRNA PIG13-DT in hepatocellular carcinoma progression.2025Cancer biology & therapyFree full text
  13. Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures.2025Cancer cell
  14. Intrahepatic Microbial Heterogeneity in Multifocal Hepatocellular Carcinoma and Its Association with Host Genomic and Transcriptomic Alterations.2025Cancer discoveryFree full text
  15. Regulator of G-protein signaling 14 (RGS14) promotes cancer growth in hepatocellular carcinoma.2025Cancer genetics
  16. Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  17. Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.2025Cancer immunology, immunotherapy : CIIFree full text
  18. Integrated Analysis of Single-Cell and Bulk RNA-Sequencing Defines N7-Methylguanosine (m7G)-Mediated Modifications' Role in Prognosis and the Tumor Immune Microenvironment in Hepatocellular Carcinoma.2025Cancer medicineFree full text
  19. Circular SNX25 encoded radioresistance augmenter facilitates DNA damage repair in hepatocellular carcinoma by targeting BAG6-GET4 interaction.2025Cell death & diseaseFree full text
  20. Targeting the TRIM14/USP14 axis enhances radiotherapy efficacy by inducing GPX4 degradation and disrupting ferroptotic defense in HCC.2025Cell death & diseaseFree full text
  21. Integrin β6/Annexin A2 axis triggers autophagy to orchestrate hepatocellular carcinoma radioresistance.2025Cell death and differentiationFree full text
  22. Catenibacteriummitsuokai promotes hepatocellular carcinogenesis by binding to hepatocytes and generating quinolinic acid.2025Cell metabolism
  23. SOX4 mediates cancer-associated fibroblasts related radioresistance in hepatocellular carcinoma.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  24. HBV-Specific TCR-T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation.2025Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  25. Establishment and Validation of the Novel Necroptosis-related Genes for Predicting Stemness and Immunity of Hepatocellular Carcinoma via Machine-learning Algorithm.2025Combinatorial chemistry & high throughput screening
  26. Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.2025European journal of clinical pharmacology
  27. Risk factors of complications after thermal ablation for hepatocellular carcinoma: the role of assessment of liver background.2025European journal of gastroenterology & hepatologyFree full text
  28. Negative serum alpha-fetoprotein at recurrence predicts good prognosis in recurrent hepatocellular carcinoma patients receiving repeated hepatectomy:a single-center retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  29. Deep learning model based on contrast-enhanced ultrasound for predicting vessels encapsulating tumor clusters in hepatocellular carcinoma.2025European radiology
  30. LASSO-empowered nomogram integrating nutritional-inflammatory-tumor characteristics predicts immunotherapy outcomes in advanced HCC: Large retrospective cohort.2025Frontiers in immunologyFree full text
  31. First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials.2025Frontiers in immunologyFree full text
  32. Integrative spatial and single-cell transcriptomics elucidate programmed cell death-driven tumor microenvironment dynamics in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  33. Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study.2025Frontiers in immunologyFree full text
  34. HBV promotes epithelial-mesenchymal transition in HCC and liver fibrosis through JNK-mediated autophagy.2025Hepatology communicationsFree full text
  35. HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion.2025Hepatology international
  36. Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors.2025International immunopharmacology
  37. Tissue-matched analysis of MRI evaluating the tumor infiltrating lymphocytes in hepatocellular carcinoma.2025International journal of cancerFree full text
  38. Comparison of Two-Dimensional Shear Wave Elastography Between Two Different Instruments for Hepatocellular Carcinoma Patients.2025Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  39. Enhancing hepatocellular carcinoma diagnosis in non-high-risk patients: a customized ChatGPT model integrating contrast-enhanced ultrasound.2025La Radiologia medica
  40. The role of contrast-enhanced ultrasound in the radiological classification of liver observations identified by CT and MRI.2025La Radiologia medica
  41. POLRMT enhances lenvatinib resistance in hepatocellular carcinoma cells by maintaining mitochondrial ATP production.2025Life sciences
  42. Diagnosis of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI Based on LI-RADS Version 2018 and LI-RADS Modifications.2025Liver international : official journal of the International Association for the Study of the Liver
  43. Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma.2025Nature communicationsFree full text
  44. Androgen receptor promotes arachidonic acid metabolism and angiogenic microenvironment in AFP-negative hepatocellular carcinoma.2025Nature communicationsFree full text
  45. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice.2025Nature microbiologyFree full text
  46. Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.2025Naunyn-Schmiedeberg's archives of pharmacology
  47. PABPN1-C5 axis promotes hepatocellular carcinoma progression via NF-κB activation.2025Oncogene
  48. Syntaxin-6 mediated autophagy confers lenvatinib resistance in hepatocellular carcinoma.2025Oncogene
  49. Idarubicin versus Epirubicin in Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: An Open-label, Randomized, Phase IV Trial.2025RadiologyRCT
  50. Using Machine Learning to Predict Advanced-Stage Progression of Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization.2025Radiology. Imaging cancerFree full text
  51. Machine Learning-Based Pathomics Model Predicts Angiopoietin-2 Expression and Prognosis in Hepatocellular Carcinoma.2025The American journal of pathology
  52. Establishment of liver cancer disease model via normothermic machine perfusion.2025The International journal of artificial organs
  53. The adverse impact of early postoperative complications after liver transplantation on long-term prognosis in patients with hepatocellular carcinoma.2025World journal of surgical oncologyFree full text
  54. Implications of ultrasound-based deep learning model for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.2024Abdominal radiology (New York)
  55. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.2024American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  56. Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma.2024Anti-cancer drugs
  57. Prediction of the early hepatocellular carcinoma development in patients with chronic hepatitis B virus infection using gadoxetic acid-enhanced magnetic resonance imaging.2024BMC cancerFree full text
  58. Effect of bile duct resection on the prognosis of patients with hepatocellular carcinoma combined with extrahepatic bile duct tumor thrombus.2024BMC cancerFree full text
  59. Deep Learning Combined with Radiologist's Intervention Achieves Accurate Segmentation of Hepatocellular Carcinoma in Dual-Phase Magnetic Resonance Images.2024BioMed research internationalFree full text
  60. Machine Learning Model Based on Prognostic Nutritional Index for Predicting Long-Term Outcomes in Patients With HCC Undergoing Ablation.2024Cancer medicineFree full text
  61. DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysis.2024Cancer medicineFree full text
  62. Quercetin-induced degradation of RhoC suppresses hepatocellular carcinoma invasion and metastasis.2024Cancer medicine
  63. N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression.2024Cancer research
  64. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.2024Clinical and translational medicineFree full text
  65. Infiltrative Vessel Co-optive Growth Pattern Induced by IQGAP3 Overexpression Promotes Microvascular Invasion in Hepatocellular Carcinoma.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  66. A Novel Oncogenic Role of Disulfidptosis-related Gene SLC7A11 in Anti-tumor Immunotherapy Response to Human Cancers.2024Current cancer drug targets
  67. Predicting One-year Recurrence of HCC based on Gadoxetic Acid-enhanced MRI by Machine Learning Models.2024Current medical imaging
  68. Hepatic Pecoma versus Hepatocellular Carcinoma In The Noncirrhotic Liver on Gd-EOB-DTPA-Enhanced MRI: A Diagnostic Challenge.2024Current medical imaging
  69. 3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma.2024European radiology
  70. Downregulation of SSR2 Enhances Hepatocellular Carcinoma Cisplatin Sensitivity via the Hippo Pathway.2024Frontiers in bioscience (Landmark edition)
  71. Multi-transcriptomics analysis of microvascular invasion-related malignant cells and development of a machine learning-based prognostic model in hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  72. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.2024Frontiers in immunologyFree full text
  73. High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT.2024Gut
  74. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.2024Hepatology (Baltimore, Md.)Free full text
  75. Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC.2024Hepatology (Baltimore, Md.)
  76. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study.2024Hepatology (Baltimore, Md.)
  77. Integrated machine learning screened glutamine metabolism-associated biomarker SLC1A5 to predict immunotherapy response in hepatocellular carcinoma.2024Immunobiology
  78. Fatty acid metabolism affects hepatocellular carcinoma progression via the PPAR-γ signaling pathway and fatty acid β-oxidation.2024International immunopharmacology
  79. Three-dimensional ultrasound fusion imaging in precise needle placement for thermal ablation of hepatocellular carcinoma.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  80. Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial.2024JAMA oncologyRCTFree full text
  81. Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.2024JAMA surgeryRCTFree full text
  82. Lobelia chinensis Lour inhibits the progression of hepatocellular carcinoma via the regulation of the PTEN/AKT signaling pathway in vivo and in vitro.2024Journal of ethnopharmacology
  83. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.2024Journal of translational medicineFree full text
  84. Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors.2024La Radiologia medica
  85. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma.2024Nature communicationsFree full text
  86. Assessment of combined serum sST2 and AFP levels in the diagnosis of hepatocellular carcinoma.2024PeerJFree full text
  87. Beyond graft function impairment after liver transplantation: the prolonged cold ischemia time impact on recurrence of hepatocellular carcinoma after liver transplantation-a single-center retrospective study.2024PeerJFree full text
  88. Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote liver tumorigenesis.2024Science advancesFree full text
  89. Letter to the editor. Comment on: A novel nomogram based on preoperative parameters to predict posthepatectomy liver failure in patients with hepatocellular carcinoma.2024Surgery
  90. Response to Letter to the Editor regarding "A novel nomogram based on preoperative parameters to predict posthepatectomy liver failure in patients with hepatocellular carcinoma".2024Surgery
  91. Development and Comparison of Prediction Models Based on Sonovue- and Sonazoid-Enhanced Ultrasound for Pathologic Grade and Microvascular Invasion in Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  92. Quantitative Parameters of Contrast-Enhanced Ultrasound Predicting the Response to Combined Immune Checkpoint Inhibitor and Anti-angiogenesis Therapies for Unresectable Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  93. Diagnostic and Prognostic Ability of Contrast-Enhanced Unltrasound and Biomarkers in Hepatocellular Carcinoma Subtypes.2024Ultrasound in medicine & biology
  94. BMI1 Silencing Liposomes Suppress Postradiotherapy Cancer Stemness against Radioresistant Hepatocellular Carcinoma.2023ACS nano
  95. Stereotactic body radiation therapy versus radiofrequency ablation in hepatocellular carcinoma: an up-date meta-analysis.2023Abdominal radiology (New York)
  96. Size-Tunable Nanoregulator-Based Radiofrequency Ablation Suppresses MDSCs and Their Compensatory Immune Evasion in Hepatocellular Carcinoma.2023Advanced healthcare materials
  97. Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma.2023AgingFree full text
  98. Elevated FAM134B expression induces radiation-sensitive in hepatocellular carcinoma.2023BMC cancerFree full text
  99. Radiofrequency ablation for pediatric recurrent hepatocellular carcinoma: a single-center experience.2023BMC medical imagingFree full text
  100. METTL3-m6A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma.2023Cancer letters
  101. Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis.2023Cancer medicineFree full text
  102. Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer.2023Cancer research
  103. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.2023Cancer research
  104. TUBB2B facilitates progression of hepatocellular carcinoma by regulating cholesterol metabolism through targeting HNF4A/CYP27A1.2023Cell death & diseaseFree full text
  105. Mechanical confinement promotes heat resistance of hepatocellular carcinoma via SP1/IL4I1/AHR axis.2023Cell reports. MedicineFree full text
  106. Influence factors on registration of three-dimensional contrast-enhanced ultrasound fusion imaging in evaluating the ablative margin - A phantom study.2023Clinical hemorheology and microcirculation
  107. Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.2023Current cancer drug targets
  108. Long-term outcomes of combined radiofrequency ablation and multipronged ethanol ablation for the treatment of unfavorable hepatocellular carcinoma.2023Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  109. Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study.2023European radiologyFree full text
  110. US LI-RADS in surveillance for recurrent hepatocellular carcinoma after curative treatment.2023European radiology
  111. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.2023European radiology
  112. Comparison of non-radiomics imaging features and radiomics models based on contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for predicting microvascular invasion in hepatocellular carcinoma within 5 cm.2023European radiologyRCT
  113. Predicting symptomatic post-hepatectomy liver failure in patients with hepatocellular carcinoma: development and validation of a preoperative nomogram.2023European radiology
  114. Radiofrequency ablation induces tumor cell dissemination in a mouse model of hepatocellular carcinoma.2023European radiology experimentalFree full text
  115. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.2023Gut
  116. Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  117. Methyltransferase 1 is required for nonhomologous end-joining repair and renders hepatocellular carcinoma resistant to radiotherapy.2023Hepatology (Baltimore, Md.)
  118. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation.2023Hepatology (Baltimore, Md.)
  119. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.2023Hepatology international
  120. A novel prognostic model based on AFP, tumor burden score and Albumin-Bilirubin grade for patients with hepatocellular carcinoma undergoing radiofrequency ablation.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  121. Treatment outcomes after radiofrequency ablation in patients with non-B non-C hepatocellular carcinoma within Milan criteria: comparison with HBV-related hepatocellular carcinoma.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  122. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization.2023Journal of cancer research and clinical oncologyFree full text
  123. Identification of BRD7 by whole-exome sequencing as a predictor for intermediate-stage hepatocellular carcinoma in patients undergoing TACE.2023Journal of cancer research and clinical oncologyFree full text
  124. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.2023Journal of cancer research and clinical oncologyFree full text
  125. Surgery or external beam radiation for solitary small hepatocellular carcinoma.2023Journal of cancer research and therapeutics
  126. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  127. Predicting Post-hepatectomy Liver Failure Preoperatively for Child-Pugh A5 Hepatocellular Carcinoma Patients by Liver Stiffness.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  128. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.2023Journal of hepatology
  129. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.2023Journal of hepatology
  130. Evaluation of Hypoxia in Hepatocellular Carcinoma Using Quantitative MRI: Significances, Challenges, and Advances.2023Journal of magnetic resonance imaging : JMRI
  131. The activation of mTOR signalling modulates DNA methylation by enhancing DNMT1 translation in hepatocellular carcinoma.2023Journal of translational medicineFree full text
  132. Strategy for Accurate Diagnosis by Contrast-Enhanced Ultrasound of Focal Liver Lesions in Patients Not at High Risk for Hepatocellular Carcinoma: A Preliminary Study.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  133. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss.2023Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyFree full text
  134. Targeting N7-methylguanosine tRNA modification blocks hepatocellular carcinoma metastasis after insufficient radiofrequency ablation.2023Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  135. Utilization of hepatitis B surface antigen-positive donors in liver transplantation for recipients with hepatocellular carcinoma: a retrospective and propensity score matching analysis.2023PeerJFree full text
  136. Predicting Infectious Complications after Percutaneous Thermal Ablation of Liver Malignancies: A 12-year Single-Center Experience.2023Radiology
  137. A novel nomogram based on preoperative parameters to predict posthepatectomy liver failure in patients with hepatocellular carcinoma.2023Surgery
  138. Value of Multimodal Data From Clinical and Sonographic Parameters in Predicting Recurrence of Hepatocellular Carcinoma After Curative Treatment.2023Ultrasound in medicine & biology
  139. Doxorubicin-Loaded UiO-66/Bi2S3 Nanocomposite-Enhanced Synergistic Transarterial Chemoembolization and Photothermal Therapy against Hepatocellular Carcinoma.2022ACS applied materials & interfaces
  140. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.2022AJR. American journal of roentgenology
  141. Feasibility of liver stiffness measured using two-dimensional shear wave elastography in assessing preoperative liver function for patients with hepatocellular carcinoma.2022Abdominal radiology (New York)
  142. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B.2022Abdominal radiology (New York)
  143. The "stiff rim" sign of hepatocellular carcinoma on shear wave elastography: correlation with pathological features and potential prognostic value.2022Abdominal radiology (New York)
  144. Radiomics models for preoperative prediction of microvascular invasion in hepatocellular carcinoma: a systematic review and meta-analysis.2022Abdominal radiology (New York)
  145. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP.2022Abdominal radiology (New York)
  146. ASO Author Reflections: Liver Stiffness by Ultrasonic Elastography-A Role in Surgical Resection for Hepatocellular Carcinoma.2022Annals of surgical oncology
  147. Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma.2022Annals of surgical oncology
  148. ASO Author Reflections: Intertumor Biological Heterogeneity Counts in Treatment Selection of Single ≤ 5 cm Hepatocellular Carcinoma.2022Annals of surgical oncology
  149. Role of Preoperational Imaging Traits for Guiding Treatment in Single ≤ 5 cm Hepatocellular Carcinoma.2022Annals of surgical oncology
  150. Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population.2022BMC cancerFree full text
  151. Identification of the origin of tumor in vein: comparison between CEUS LI-RADS v2017 and v2016 for patients at high risk.2022BMC medical imagingFree full text
  152. Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017.2022BMC medical imagingFree full text
  153. Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma.2022Cancer immunology research
  154. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2+ γδ T cell can be a promising complement.2022Clinical and translational medicineFree full text
  155. Identification of DNA methylation signatures for hepatocellular carcinoma detection and microvascular invasion prediction.2022European journal of medical researchFree full text
  156. A nomogram based on multi-modal ultrasound for prediction of microvascular invasion and recurrence of hepatocellular carcinoma.2022European journal of radiology
  157. The value of liver stiffness measured by two-dimensional shear wave elastography for predicting symptomatic posthepatectomy liver failure in patients with hepatocellular carcinoma.2022European journal of radiology
  158. Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective.2022Frontiers in immunologyFree full text
  159. The C1q-ApoE complex: A new hallmark pathology of viral hepatitis and nonalcoholic fatty liver disease.2022Frontiers in immunologyFree full text
  160. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study.2022Frontiers in immunologyFree full text
  161. Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images.2022Hepatology internationalFree full text
  162. Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma.2022Hepatology internationalFree full text
  163. Preoperative prognostic value of alfa-fetoprotein density in patients with hepatocellular carcinoma undergoing radiofrequency ablation.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  164. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  165. Ultrasound-guided percutaneous radiofrequency ablation in treatment of neuroendocrine tumor liver metastases:a single-center experience.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  166. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.2022Journal of cancer research and clinical oncologyFree full text
  167. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.2022Journal of cancer research and therapeutics
  168. pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors.2022Journal of controlled release : official journal of the Controlled Release Society
  169. Personalized treatment for hepatocellular carcinoma: Current status and future perspectives.2022Journal of gastroenterology and hepatology
  170. Comparison of Hepatic Resection with Percutaneous Ablation for Hepatocellular Carcinoma in the Caudate Lobe Within Milan Criteria.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  171. Single-cell transcriptomics reveals the role of Macrophage-Naïve CD4 + T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma.2022Journal of translational medicineFree full text
  172. Contrast-Enhanced Ultrasound-Based Nomogram: A Potential Predictor of Individually Postoperative Early Recurrence for Patients With Combined Hepatocellular-Cholangiocarcinoma.2022Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  173. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.2022Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  174. Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017.2022La Radiologia medica
  175. Prediction of microvascular invasion in hepatocellular carcinoma with expert-inspiration and skeleton sharing deep learning.2022Liver international : official journal of the International Association for the Study of the Liver
  176. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  177. N6-methyladenosine (m6A) in 18S rRNA promotes fatty acid metabolism and oncogenic transformation.2022Nature metabolism
  178. microRNA-375 inhibits the malignant behaviors of hepatic carcinoma cells by targeting NCAPG2.2022Neoplasma
  179. Generation of a human induced pluripotent stem cell line (SYSUTFi001-A) from infiltrating cytotoxic T cells in hepatocellular carcinoma (HCC).2022Stem cell research
  180. Prognostic Role of Albumin-Bilirubin Grade in Hepatocellular Carcinoma After Ultrasound-guided Percutaneous Radiofrequency Ablation: A Single-center Experience Over a Decade.2022Surgical laparoscopy, endoscopy & percutaneous techniques
  181. Contrast-enhanced ultrasound-based ultrasomics score: a potential biomarker for predicting early recurrence of hepatocellular carcinoma after resection or ablation.2022The British journal of radiologyFree full text
  182. Circulating tumour cell counts and ultrasomics signature-based nomogram for preoperative prediction of early recurrence of hepatocellular carcinoma after radical treatment.2022The British journal of radiologyFree full text
  183. Feeding Vessel Ablation: A Novel Subsegmental Devascularization Technique for the Treatment of Hepatocellular Carcinoma Located at the Liver Marginal Angle.2022Ultrasound in medicine & biology
  184. Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma.2022World journal of surgical oncologyFree full text
  185. Preoperative Pathological Grading of Hepatocellular Carcinoma Using Ultrasomics of Contrast-Enhanced Ultrasound.2021Academic radiology
  186. Development of a prognostic model for hepatocellular carcinoma using genes involved in aerobic respiration.2021AgingFree full text
  187. Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series.2021Annals of palliative medicine
  188. Microvascular Invasion Status and Its Survival Impact in Hepatocellular Carcinoma Depend on Tissue Sampling Protocol.2021Annals of surgical oncology
  189. An Alternative Surgical Technique of Native Hepatectomy in Liver Transplantation.2021Annals of transplantationFree full text
  190. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study2021BMC cancerFree full text
  191. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.2021BMC cancerFree full text
  192. Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth.2021Cancer letters
  193. METTL1 promotes hepatocarcinogenesis via m7 G tRNA modification-dependent translation control.2021Clinical and translational medicineFree full text
  194. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.2021European radiologyFree full text
  195. Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI.2021European radiology
  196. Inter-reader agreement of CEUS LI-RADS among radiologists with different levels of experience.2021European radiology
  197. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.2021European radiology
  198. Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC.2021European radiology
  199. Treatment effect of radiofrequency ablation versus liver transplantation and surgical resection for hepatocellular carcinoma within Milan criteria: a population-based study.2021European radiology
  200. Upregulation of a novel LncRNA AC104958.2 stabilized by PCBP2 promotes proliferation and microvascular invasion in hepatocellular carcinoma.2021Experimental cell research
  201. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  202. Prognostic significance and function of MCM10 in human hepatocellular carcinoma.2021Future oncology (London, England)
  203. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells.2021GutFree full text
  204. Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism.2021Hepatology (Baltimore, Md.)
  205. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.2021Hepatology (Baltimore, Md.)Free full text
  206. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.2021International journal of clinical oncology
  207. Percutaneous ethanol injection enhanced the efficacy of radiofrequency ablation in the treatment of HCC: an insight into the mechanism of ethanol action.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  208. Percutaneous thermal ablation of hepatic tumors: local control efficacy and risk factors for artificial ascites failure.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  209. Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy.2021Investigational new drugsFree full text
  210. Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma.2021JAMA network openFree full text
  211. Activated but impaired IFN-γ production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma.2021Journal for immunotherapy of cancerFree full text
  212. Three-day postoperative antibiotics reduces post-hepatectomy infection rate in hepatitis B virus-related hepatocellular carcinoma.2021Journal of gastroenterology and hepatology
  213. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  214. Combined Use of Transjugular Intrahepatic Portosystemic Shunt and Transarterial Chemoembolization in the Treatment of Esophageal and Gastric Variceal Bleeding: A Retrospective Study of 80 Patients with Hepatocellular Carcinoma and Portal Hy2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  215. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity.2021Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  216. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
  217. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?2021Radiology
  218. Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing.2021The British journal of radiologyFree full text
  219. Comment on: Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study.2021The British journal of surgery
All its trials on ClinicalTrials.gov, any status54
  1. DEB-TACE vs cTACE in HCC After TIPSRecruitingNCT07322848Lead sponsorPhase 3Start 2025-12
  2. Individualized Surgical Guidance in HCC-BDTTCompletedNCT07483242Lead sponsorStart 2024-08
  3. Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular CarcinomaCompletedNCT07315022Lead sponsorPhase 4Start 2024-08
  4. Different Abbreviated MRI for Hepatocellular Carcinoma DiagnosisCompletedNCT06663904Lead sponsorStart 2021-01
  5. Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC DownstagingActive, not recruitingNCT07581769Lead sponsorStart 2018-01
  6. CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCCCompletedNCT07449065Lead sponsorStart 2018-06
  7. Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular CarcinomaStatus unknownNCT02616926Lead sponsorN/AStart 2015-12
  8. Using Machine Learning to Identify Responders to TACE or HAIC for uHCCCompletedNCT07368530Lead sponsorStart 2015-01
  9. VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated PathwayStatus unknownNCT01892072Lead sponsorStart 2012-10
  10. Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation TherapyStatus unknownNCT01668381Lead sponsorStart 2012-08
  11. TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskRecruitingNCT07487662Lead (inferred)Phase 2Start 2026-03
  12. SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.Not yet recruitingNCT06739317Lead (inferred)Phase 2/Phase 3Start 2025-01
  13. SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)Not yet recruitingNCT05718232Lead (inferred)Phase 3Start 2023-03
  14. Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular CarcinomaRecruitingNCT06788353Lead (inferred)Start 2023-03
  15. Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCCRecruitingNCT04615143Lead (inferred)Phase 2Start 2020-12
  16. Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular CarcinomaStatus unknownNCT05010434Lead (inferred)Phase 2Start 2021-08
  17. Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver ResectionSuspendedNCT03990974Lead (inferred)Phase 3Start 2020-09
  18. SBRT Versus Ablation for Perivascular Hepatocellular CarcinomaStatus unknownNCT04434989Lead (inferred)N/AStart 2020-06
  19. Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCCStatus unknownNCT04143191Lead (inferred)Phase 3Start 2019-09
  20. TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCCStatus unknownNCT03905967Lead (inferred)Phase 3Start 2019-06
  21. TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular CarcinomaCompletedNCT04103398Lead (inferred)Phase 3Start 2019-10
  22. Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular CarcinomaStatus unknownNCT05889949Lead (inferred)Start 2019-06
  23. Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTTWithdrawnNCT05592197Lead (inferred)N/AStart 2018-10
  24. Randomized Study of Adjuvant Radiotherapy After Curative Resection of HCC With Narrow Margin (RAISE)Status unknownNCT03732105Lead (inferred)N/AStart 2018-08
  25. TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver TransplantationStatus unknownNCT04677088Lead (inferred)Phase 1Start 2018-03
  26. RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II TrialStatus unknownNCT03067493Lead (inferred)Phase 2Start 2017-07
  27. Preoperative Prediction of Microvascular Invasion in Hepatocellular CarcinomaStatus unknownNCT03198975Lead (inferred)Start 2017-06
  28. Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular CarcinomaStatus unknownNCT02755311Lead (inferred)Phase 3Start 2014-03
  29. Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular CarcinomaCompletedNCT00844454Lead (inferred)N/AStart 2008-05
  30. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  31. GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 ExpressionRecruitingNCT03198546Study sitePhase 1Start 2017-07
  32. A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250Study siteStart 2024-07
  33. Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With ExplainabilityCompletedNCT06760494Study siteStart 2023-11
  34. Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure PredictionStatus unknownNCT06031818Study siteStart 2023-12
  35. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Study sitePhase 2Start 2022-04
  36. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  37. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  38. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  39. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  40. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Study sitePhase 2Start 2020-01
  41. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  42. NeuWave Microwave Ablation HCC China StudyCompletedNCT03783871Study siteN/AStart 2019-02
  43. Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCCWithdrawnNCT03744247Study sitePhase 3Start 2019-04
  44. Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Study sitePhase 2/Phase 3Start 2019-10
  45. Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan CriteriaStatus unknownNCT03469479Study sitePhase 3Start 2018-03
  46. Sirolimus-based Immunosuppression Treatment Regimen for Liver TransplantationStatus unknownNCT03500848Study sitePhase 2/Phase 3Start 2018-05
  47. HAIC of FOLFOX vs. HAIC of OXA for Advanced HCCStatus unknownNCT03468231Study sitePhase 3Start 2018-03
  48. A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver TransplantationWithdrawnNCT03634683Study sitePhase 1/Phase 2Start 2018-08
  49. A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver TransplantationCompletedNCT02686372Study sitePhase 1Start 2018-05
  50. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  51. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  52. Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma HugeStatus unknownNCT03277716Study siteN/AStart 2017-12
  53. HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCCCompletedNCT02856126Study sitePhase 3Start 2016-08
  54. Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCCCompletedNCT02774187Study sitePhase 3Start 2016-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 52 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
52
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 111120212022: 8820222023: 8820232024: 121220242025: 12122025

16 hospitals in Guangzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  2. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  3. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  4. Not yet recruiting
    Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
    Phase
    N/A
    Started
    2025-08
    Registry
    NCT07098949

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsImaging & AI
Departments in papersGastroenterology / hepatologyMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led52
  1. Early Detection of Myocardial Dysfunction by Two-Dimensional Speckle Tracking Echocardiography and Myocardial Work in Patients With Gastroenteropancreatic Neuroendocrine Neoplasms.2026Journal of clinical ultrasound : JCU
  2. An LCN2-Dependent Positive-Feedback Loop Between Gastric Cancer Cells and Tumor-Associated-Macrophages Mediates Lymphangiogenesis and Lymphatic Metastasis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Identification of gastroenteropancreatic neuroendocrine tumor patients with high liver tumor burden based on clinicopathological features.2025BMC cancerFree full text
  4. DNA methylation profiles predicting response to anti-PD-1-based treatment in patients with advanced gastric cancer.2025BMC medicineFree full text
  5. N7-methylguanosine tRNA modification promotes gastric cancer progression by activating SDHAF4-dependent mitochondrial oxidative phosphorylation.2025Cancer letters
  6. Intratumoral Fusobacterium nucleatum Recruits Tumor-Associated Neutrophils to Promote Gastric Cancer Progression and Immune Evasion.2025Cancer researchFree full text
  7. Enhanced ZBTB10 expression induced by betulinic acid inhibits gastric cancer progression by inactivating the ARRDC3/ITGB4/PI3K/AKT pathway.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  8. Addition of immunotherapy to perioperative chemotherapy for resectable gastric and gastroesophageal junction cancer: a meta-analysis of phase 2/3 trials.2025Frontiers in immunologyFree full text
  9. First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials.2025Frontiers in immunologyFree full text
  10. Clinical Efficacy and Safety of Apatinib Combined with Irinotecan in HER2-negative Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First-Line Treatment Failure: A Single-Arm, Single-Center Retrospective Stud2025Journal of gastrointestinal cancerFree full text
  11. Decoding the m6A epitranscriptomic landscape for biotechnological applications using a direct RNA sequencing approach.2025Nature communicationsFree full text
  12. Gastric cancer adapts high lipid microenvironment via suppressing PPARG-FABP1 axis after arriving in the lymph node.2025Redox biologyFree full text
  13. Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study.2025Seminars in oncology
  14. Value of orthogonal axial MR images in preoperative T staging of gastric cancer.2024Abdominal radiology (New York)
  15. DDR1 Drives Malignant Progression of Gastric Cancer by Suppressing HIF-1α Ubiquitination and Degradation.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  16. ITGB5 facilitates gastric cancer metastasis by promoting TGFBR2 endosomal recycling.2024Cancer letters
  17. Tumor-secreted LCN2 impairs gastric cancer progression via autocrine inhibition of the 24p3R/JNK/c-Jun/SPARC axis.2024Cell death & diseaseFree full text
  18. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.2024Cell reports. MedicineFree full text
  19. RP11-789C1.1 inhibits gastric cancer cell proliferation and accelerates apoptosis via the ATR/CHK1 signaling pathway.2024Chinese medical journalFree full text
  20. Upregulation of NPC1 and its association with poor prognosis in gastric cancer.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  21. Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer.2024Journal of translational medicineFree full text
  22. CircGLIS3 promotes gastric cancer progression by regulating the miR-1343-3p/PGK1 pathway and inhibiting vimentin phosphorylation.2024Journal of translational medicineFree full text
  23. Circulating Regulatory T Cells: A Novel Marker Associated with Liver Metastasis and the Treatment Response of Transarterial Embolization in Gastroenteropancreatic Neuroendocrine Tumors.2024NeuroendocrinologyFree full text
  24. NIT2 dampens BRD1 phase separation and restrains oxidative phosphorylation to enhance chemosensitivity in gastric cancer.2024Science translational medicine
  25. Gastric cancer immune microenvironment score predicts neoadjuvant chemotherapy efficacy and prognosis.2024The journal of pathology. Clinical researchFree full text
  26. EGCG-LYS Fibrils-Mediated CircMAP2K2 Silencing Decreases the Proliferation and Metastasis Ability of Gastric Cancer Cells in Vitro and in Vivo.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  27. Personalized immune subtypes based on machine learning predict response to checkpoint blockade in gastric cancer.2023Briefings in bioinformatics
  28. HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.2023Cancer scienceFree full text
  29. Twin-grasper assisted mucosal inverted closure achieves complete healing of large perforations after gastric endoscopic full-thickness resection.2023Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy SocietyFree full text
  30. Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  31. Multiplex immunohistochemistry defines two cholesterol metabolism patterns predicting immunotherapeutic outcomes in gastric cancer.2023Journal of translational medicineFree full text
  32. Circ-E-Cad encodes a protein that promotes the proliferation and migration of gastric cancer via the TGF-β/Smad/C-E-Cad/PI3K/AKT pathway.2023Molecular carcinogenesisFree full text
  33. Circular MTHFD2L RNA-encoded CM-248aa inhibits gastric cancer progression by targeting the SET-PP2A interaction.2023Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  34. Chitosan-Gelatin-EGCG Nanoparticle-Meditated LncRNA TMEM44-AS1 Silencing to Activate the P53 Signaling Pathway for the Synergistic Reversal of 5-FU Resistance in Gastric Cancer.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  35. m6 A-mediated regulation of PBX1-GCH1 axis promotes gastric cancer proliferation and metastasis by elevating tetrahydrobiopterin levels.2022Cancer communications (London, England)Free full text
  36. PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer.2022Cancer letters
  37. m6A modification-mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability.2022Cancer scienceFree full text
  38. Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms.2022Endocrine
  39. Single-cell RNA-seq dissecting heterogeneity of tumor cells and comprehensive dynamics in tumor microenvironment during lymph nodes metastasis in gastric cancer.2022International journal of cancer
  40. The association of immune cell infiltration and prognostic value of tertiary lymphoid structures in gastric cancer.2022Neoplasma
  41. CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies.2022Oncogene
  42. A CT-based nomogram for predicting the malignant potential of primary gastric gastrointestinal stromal tumors preoperatively.2021Abdominal radiology (New York)
  43. The risk of lymph node metastasis in gastric cancer conforming to indications of endoscopic resection and pylorus-preserving gastrectomy: a single-center retrospective study.2021BMC cancerFree full text
  44. Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data.2021BMC cancerFree full text
  45. DAPK3 inhibits gastric cancer progression via activation of ULK1-dependent autophagy.2021Cell death and differentiationFree full text
  46. KLF5 Is Activated by Gene Amplification in Gastric Cancer and Is Essential for Gastric Cell Proliferation.2021CellsFree full text
  47. Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2-Hippo signaling pathway.2021Clinical and translational medicineFree full text
  48. Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms.2021Endocrine
  49. ZIPK activates the IL-6/STAT3 signaling pathway and promotes cisplatin resistance in gastric cancer cells.2021FEBS open bioFree full text
  50. Diagnostic and prognostic value of HOXC family members in gastric cancer.2021Future oncology (London, England)
  51. HOTAIR plays an oncogenic role in gastric cancer through microRNA and SNP.2021Neoplasma
  52. Trim47 overexpression correlates with poor prognosis in gastric cancer.2021Neoplasma
Chinese-language papers (not in the count)2
  1. [Clinical significance of skeletonization dissection for No.12 lymph nodes after neoadjuvant therapy in advanced gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Related factors of postoperative complications of radical resection for adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status22
  1. Safety of 250ml Preoperative Carbohydrate Drink in Gastric Cancer PatientsCompletedNCT02815150Lead sponsorN/AStart 2016-04
  2. Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic SurgeryStatus unknownNCT02426762Lead sponsorPhase 2Start 2015-02
  3. The Predictive Value of Complement C3 in Patients With Advanced Gastric CancerCompletedNCT02425930Lead sponsorStart 2013-08
  4. The Long-term Effect of D4 Lymphadenectomy for Gastric CancerStatus unknownNCT02423278Lead sponsorPhase 2/Phase 3Start 2010-01
  5. Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI TumorStatus unknownNCT01048463Lead (inferred)Phase 3Start 2009-12
  6. Acupuncture Combined With Chemotherapy for Gastric Cancer After SurgeryNot yet recruitingNCT07098949Study siteN/AStart 2025-08
  7. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  8. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  9. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  10. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  11. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  12. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  13. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  14. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  15. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal MetastasisStatus unknownNCT04222114Study sitePhase 3Start 2020-10
  16. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  17. Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant ChemotherapyCompletedNCT04360577Study siteN/AStart 2020-05
  18. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  19. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  20. Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot StudyCompletedNCT03753399Study siteN/AStart 2019-01
  21. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  22. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 5 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 3.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 3320242025: 002025

8 hospitals in Guangzhou for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Guangzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies.2022Proceedings of the National Academy of Sciences of the United States of America
Earlier papers (2016–2020)1
  1. Role of RB1 in human embryonic stem cell-derived retinal organoids.2020Developmental biology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Guangzhou for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 33 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.5%.

Papers led
33
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 7720222023: 5520232024: 8820242025: 772025

33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led33
  1. LIPA-driven reprogramming of tumor-associated macrophages shapes an immunosuppressive microenvironment in osteosarcoma.2026International immunopharmacology
  2. LncDARS-AS1 Regulates ATP1A1 Stability and Enhances Na+/K+ ATPase Activity to Promote Osteosarcoma Metastasis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  3. The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A.2025Cancer letters
  4. Troxerutin suppresses the stemness of osteosarcoma via the CD155/SRC/β-catenin signaling axis.2025Cellular & molecular biology letters
  5. Impact of environmental pollution on human health: Investigating the role of Polycyclic Aromatic Hydrocarbons in pediatric osteosarcoma.2025Ecotoxicology and environmental safety
  6. A prediction model of pulmonary metastasis risk in pediatric patients with stage IIB osteosarcoma in the long bone of extremities.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  7. Multiomics integration analysis identifies tumor cell-derived MIF as a therapeutic target and potentiates anti-PD-1 therapy in osteosarcoma.2025Journal for immunotherapy of cancer
  8. Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma.2025Journal of translational medicine
  9. SNPs Give LACTB Oncogene-Like Functions and Prompt Tumor Progression via Dual-Regulating p53.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  10. Predicting prognosis and immune status in sarcomas by identifying necroptosis-related lncRNAs.2024Aging
  11. High expression of SRSF1 facilitates osteosarcoma progression and unveils its potential mechanisms.2024BMC cancer
  12. Targeting NAT10 inhibits osteosarcoma progression via ATF4/ASNS-mediated asparagine biosynthesis.2024Cell reports. Medicine
  13. miR-1293 suppresses osteosarcoma progression by modulating drug sensitivity in response to cisplatin treatment.2024International immunopharmacology
  14. Comparison of oncological and functional outcomes in Lower-limb osteosarcoma pediatric patients: a large single-center retrospective cohort study.2024International journal of surgery (London, England)
  15. Prognostic and predictive value of super-enhancer-derived signatures for survival and lung metastasis in osteosarcoma.2024Journal of translational medicine
  16. Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma.2024Journal of translational medicine
  17. Autologous menisci-cruciate ligament composite as a flap for soft tissue reconstruction following malignant bone tumor resection around the knee.2023Cancer medicine
  18. Super-enhancer-driven MLX mediates redox balance maintenance via SLC7A11 in osteosarcoma.2023Cell death & disease
  19. A novel stratification framework based on anoikis-related genes for predicting the prognosis in patients with osteosarcoma.2023Frontiers in immunology
  20. METTL1/WDR4-mediated tRNA m7G modification and mRNA translation control promote oncogenesis and doxorubicin resistance.2023Oncogene
  21. T52 attenuates oncogenic STAT3 signaling and suppresses osteosarcoma.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. Prospero homeobox 1 promotes proliferation, migration, and invasion of osteosarcoma cells and its clinical significance.2022Bioengineered
  23. Overexpression of BRINP3 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration via MAP4 in Osteosarcoma.2022Disease markers
  24. METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma.2022EBioMedicine
  25. The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma.2022Frontiers in immunology
  26. M6A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes Wnt signaling to facilitate osteosarcoma progression.2022Oncogene
  27. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies.2022Proceedings of the National Academy of Sciences of the United States of America
  28. Survival after pulmonary metastasectomy for relapsed osteosarcoma.2022The Journal of thoracic and cardiovascular surgery
  29. Synergistic Anticancer Effects of Cisplatin Combined with Combretastatin A4 Phosphate on Human Osteosarcoma-Xenografted Mice.2021Cells, tissues, organs
  30. Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma.2021European journal of pharmacology
  31. GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma.2021Journal of orthopaedic surgery and research
  32. Experience with periprosthetic infection after limb salvage surgery for patients with osteosarcoma.2021Journal of orthopaedic surgery and research
  33. A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway.2021Oncogene
Earlier papers (2016–2020)23
  1. Feasibility of multi-parametric magnetic resonance imaging combined with machine learning in the assessment of necrosis of osteosarcoma after neoadjuvant chemotherapy: a preliminary study.2020BMC cancer
  2. Characterization and Management of Juxtaglomerular Cell Tumor: Analysis of 9 Cases and Literature Review.2020Balkan medical journal
  3. EFEMP1 as a Potential Biomarker for Diagnosis and Prognosis of Osteosarcoma.2020BioMed research international
  4. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma.2020Cancer medicine
  5. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.2020Clinical cancer research : an official journal of the American Association for Cancer Research
  6. Comprehensive metabolomic profiling of osteosarcoma based on UHPLC-HRMS.2020Metabolomics : Official journal of the Metabolomic Society
  7. Plastic lengthening amputation with vascularized bone grafts in children with bone sarcoma: a preliminary report.2020World journal of surgical oncology
  8. Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1α.2019Human cell
  9. Comparison of clinical features, management and outcomes of osteosarcoma located in proximal fibula and proximal tibia: a propensity score matching analysis.2018BMC cancer
  10. Predictive value of dynamic change of haemoglobin levels during therapy on treatment outcomes in patients with Enneking stage IIB extremity osteosarcoma.2018BMC cancer
  11. Brazilin induces FOXO3A-dependent autophagic cell death by disturbing calcium homeostasis in osteosarcoma cells.2018Cancer chemotherapy and pharmacology
  12. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.2018Cancer chemotherapy and pharmacology
  13. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway.2018Cell death & disease
  14. Degalactotigonin, a Natural Compound from Solanum nigrum L., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation-Mediated Repression of the Hedgehog/Gli1 Pathway.2018Clinical cancer research : an official journal of the American Association for Cancer Research
  15. Genetic and clonal dissection of osteosarcoma progression and lung metastasis.2018International journal of cancer
  16. CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.2018Oncogene
  17. Correlation between apparent diffusion coefficient and histopathology subtypes of osteosarcoma after neoadjuvant chemotherapy.2017Acta radiologica (Stockholm, Sweden : 1987)
  18. lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition.2017Cancer letters
  19. DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma.2017Cancer medicine
  20. Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling.2017European review for medical and pharmacological sciences
  21. MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.2017Oncogene
  22. LDOC1 regulates Wnt5a expression and osteosarcoma cell metastasis and is correlated with the survival of osteosarcoma patients.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  23. Down-regulation of tumor endothelial marker 8 suppresses cell proliferation mediated by ERK1/2 activity.2016Scientific reports
All its trials on ClinicalTrials.gov, any status2
  1. Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat OsteosarcomaStatus unknownNCT01669369Lead (inferred)Phase 4Start 2013-01
  2. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 9 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.7%.

Papers led
9
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 1120242025: 332025

13 hospitals in Guangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05461664

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  2. Recruiting
    A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05464875

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  3. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led9
  1. Integrating surgery and targeted therapies in the management of recurrent/metastatic gastrointestinal stromal tumors.2025Cancer
  2. Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study.2025Future oncology (London, England)
  3. The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation.2025The oncologist
  4. CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.2024European radiology
  5. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.2023Advances in therapy
  6. Diagnosis, Treatment, and Prognosis of Patients with Primary Familial Gastrointestinal Stromal Tumor: A Case Report and Literature Review.2023The oncologist
  7. [18F]FAPI-42 PET/CT versus [18F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors.2022European journal of nuclear medicine and molecular imaging
  8. A CT-based nomogram for predicting the malignant potential of primary gastric gastrointestinal stromal tumors preoperatively.2021Abdominal radiology (New York)
  9. A concealed inguinal presentation of a gastrointestinal stromal tumor (GIST): a case report and literature review.2021BMC surgery
Earlier papers (2016–2020)8
  1. Differential diagnosis of liver metastases of gastrointestinal stromal tumors from colorectal cancer based on combined tumor biomarker with features of conventional ultrasound and contrast-enhanced ultrasound.2020Abdominal radiology (New York)
  2. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.2020Cancer
  3. Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.2020EBioMedicine
  4. Thermal ablation versus hepatic resection for the treatment of liver metastases from gastrointestinal stromal tumors: a retrospective study.2020International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  5. [Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.2019European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  7. Predictive ability of prognostic nutritional index in surgically resected gastrointestinal stromal tumors: a propensity score matching analysis.2019Japanese journal of clinical oncology
  8. Feasibility of endoscopic submucosal dissection for upper gastrointestinal submucosal tumors treatment and value of endoscopic ultrasonography in pre-operation assess and post-operation follow-up: a prospective study of 224 cases in a singl2016Surgical endoscopy
All its trials on ClinicalTrials.gov, any status13
  1. The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTsStatus unknownNCT06431451Lead sponsorStart 2024-06
  2. Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different GenotypesCompletedNCT06628739Lead sponsorStart 2017-07
  3. Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic SurgeryStatus unknownNCT02426762Lead sponsorPhase 2Start 2015-02
  4. Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LMCompletedNCT06038552Lead sponsorStart 2002-01
  5. A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal TumorsRecruitingNCT05464875Lead (inferred)Start 2022-07
  6. Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRARecruitingNCT05461664Lead (inferred)Start 2022-07
  7. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  8. Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world StudyStatus unknownNCT05440357Study siteStart 2022-07
  9. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04
  10. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  11. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  12. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03
  13. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Study siteN/AStart 2016-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery
Chinese-language papers (not in the count)2
  1. [Comparison of the modified Kadish, AJCC T and Dulguerov T staging systems for olfactory neuroblastoma: analysis of the SEER database].2025Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [Primary experience and discussion on the treatment of esthesioneuroblastoma].2021Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Earlier papers (2016–2020)5
  1. A novel nomogram to predict the overall survival in esthesinoeroblastoma.2020BMC cancer
  2. GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN.2019Biochemical and biophysical research communications
  3. NLGN3 promotes neuroblastoma cell proliferation and growth through activating PI3K/AKT pathway.2019European journal of pharmacology
  4. [New system combining Hyams grading system and modified Kadish stage to evaluate the progress of esthesioneuroblastoma].2019Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery
  5. miR-1303 promotes the proliferation of neuroblastoma cell SH-SY5Y by targeting GSK3β and SFRP1.2016Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

9 hospitals in Guangzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 18 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 4420222023: 2220232024: 3320242025: 662025

14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskStem cell transplantDrug combinations
Departments in papersPathology / laboratory medicine
Papers it led18
  1. Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma.2026Archives of medical research
  2. The Relationship between Cytogenetic Abnormalities and Clinical Biological Characteristics in Newly Diagnosed Multiple Myeloma.2025Annals of clinical and laboratory science
  3. MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma.2025Annals of medicineFree full text
  4. Evolving treatments and outcomes in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a real-world study in China.2025BMC cancerFree full text
  5. Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.2025Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  6. Integrative analysis of bulk and single-cell gene expression profiles to identify bone marrow mesenchymal cell heterogeneity and prognostic significance in multiple myeloma.2025Journal of translational medicineFree full text
  7. Crystal-storing histiocytosis of multiple myeloma with a novel multi-exon deletion of WRN: A case report and mini review of literature.2025Pathology, research and practice
  8. Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization.2024Annals of hematologyFree full text
  9. Early M-protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma.2024British journal of haematology
  10. Cuproptosis-Related Gene Signature Contributes to Prognostic Prediction and Immunosuppression in Multiple Myeloma.2024Molecular biotechnology
  11. Prolonged infusion time of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) as a mobilization regimen may improve mobilization efficiency in newly diagnosed multiple myeloma patients: a single center experience.2023Annals of medicineFree full text
  12. RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells.2023Medical oncology (Northwood, London, England)Free full text
  13. Comprehensive bioinformatics analysis reveals the hub genes and pathways associated with multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  14. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.2022Integrative cancer therapiesRCTFree full text
  15. Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.2022Journal of cancer research and clinical oncologyFree full text
  16. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.2022Molecular cancer therapeuticsFree full text
  17. Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.2021Cancer medicineFree full text
  18. Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma.2021Cancer medicineFree full text
Chinese-language papers (not in the count)5
  1. [Investigation of the immune profile of multiple myeloma patients achieving long-term survival after autologous stem cell transplantation].2024Zhonghua nei ke za zhi
  2. [Interpretation of treatment for newly diagnosed multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].2022Zhonghua nei ke za zhi
  3. [New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: a single center retrospective study of 300 cases].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Efficacy and safety of autologous hematopoietic stem cell transplantation in elderly multiple myeloma patients: a single center retrospective study].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  5. [Problems and progress of autologous hematopoietic stem cell transplantation in multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status5
  1. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  2. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  3. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  4. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  5. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyStem cell transplantMRD & relapse
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

5 hospitals in Guangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenDiagnosis & prognosisTreatment regimens

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 5 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 1.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 002025

23 hospitals in Guangzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Papers it led5
  1. Enhancing thalassemia gene carrier identification in non-anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning.2024European journal of haematology
  2. TT@MHA: A machine learning-based webpage tool for discriminating thalassemia trait from microcytic hypochromic anemia patients.2023Clinica chimica acta; international journal of clinical chemistry
  3. An online alpha-thalassemia carrier discrimination model based on random forest and red blood cell parameters for low HbA2 cases.2022Clinica chimica acta; international journal of clinical chemistry
  4. Long-read sequencing on the SMRT platform enables efficient haplotype linkage analysis in preimplantation genetic testing for β-thalassemia.2022Journal of assisted reproduction and genetics
  5. Successful four-factor preimplantation genetic testing: α- and β-thalassemia, human leukocyte antigen typing, and aneuploidy screening.2021Systems biology in reproductive medicine
Chinese-language papers (not in the count)1
  1. [Clinical value of PCR-flow Fluorescence Hybridization in Prenatal Genetic Diagnosis of Thalassemia].2021Zhongguo shi yan xue ye xue za zhi
Earlier papers (2016–2020)9
  1. Eleven healthy live births: a result of simultaneous preimplantation genetic testing of α- and β-double thalassemia and aneuploidy screening.2020Journal of assisted reproduction and genetics
  2. Karyomapping in preimplantation genetic testing for β-thalassemia combined with HLA matching: a systematic summary.2019Journal of assisted reproduction and genetics
  3. Multiple displacement amplification as the first step can increase the diagnostic efficiency of preimplantation genetic testing for monogenic disease for β-thalassemia.2019The journal of obstetrics and gynaecology research
  4. The phenomena of balanced effect between α-globin gene and of β-globin gene.2018BMC medical genetics
  5. Correction of β-thalassemia mutant by base editor in human embryos.2017Protein & cell
  6. Role of Three-Dimensional Speckle Tracking Echocardiography in the Quantification of Myocardial Iron Overload in Patients with Beta-Thalassemia Major.2016Echocardiography (Mount Kisco, N.Y.)
  7. [Clinical analysis of preimplantation genetic diagnosis with HLA matching for beta-thalassemia].2016Zhonghua fu chan ke za zhi
  8. [Analysis of hematological phenotype and genotype of 23 patients from Guangdong with co-inherited hemoglobin Hb Westmead and β-thalassemia].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  9. [Preimplantation genetic diagnosis for carriers of thalassemia and chromosomal abnormality].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisImagingOptic nerve & vision
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 28 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 5.6%.

Papers led
28
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 6620232024: 9920242025: 552025

8 hospitals in Guangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesThymus & thymectomyStandard immunotherapyEye-only (ocular) myasthenia
Departments in papersNeurologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led28
  1. Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.2026Annals of neurology
  2. Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit.2025BMC neurologyFree full text
  3. Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta-Analysis.2025European journal of neurologyFree full text
  4. Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study.2025International immunopharmacology
  5. Predictive Value of Perioperative Blood Lactic Acid Levels for Postoperative Crisis in Myasthenia Gravis Patients Undergoing Thymectomy.2025Muscle & nerveFree full text
  6. Multiple concurrent opportunistic infections in patient with myasthenia gravis: A case report.2025VirulenceFree full text
  7. Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.2024Acta neurologica Belgica
  8. Thymoma-associated autoimmune encephalitis with myasthenia gravis: Case series and literature review.2024CNS neuroscience & therapeuticsFree full text
  9. Therapeutic Effect and Side Effects of Pharmacotherapy in Patients With Parkinson Disease and Myasthenia Gravis: A Systematic Review of Case Reports and Case Series Studies.2024Clinical therapeutics
  10. Combined Use of Magnetization Transfer Ratio and T2-Mapping to Evaluate Extraocular Muscle Pathophysiology in Myasthenia Gravis with Ophthalmoparesis.2024International journal of medical sciencesFree full text
  11. Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.2024Journal of neuroimmunology
  12. Conventional dendritic cells are more activated in the hyperplastic Thymus of myasthenia gravis patients.2024Journal of neuroimmunology
  13. Targeting HIF-1α alleviates the inflammatory responses and rebuilds the CD4+ T cell subsets balance in the experimental autoimmune myasthenia gravis inflammation model via regulating cellular and humoral immunity.2024Life sciences
  14. Extraocular muscle volume on time-of-flight magnetic resonance angiography in patients with myasthenia gravis.2024Muscle & nerve
  15. Clinical characteristics and therapeutic effect of myasthenia gravis coexisting with thyroid eye disease.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  16. Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis.2023Acta neurologica Belgica
  17. Case Report: Extraocular muscles paralysis associated with GAD65 antibody: a case series study.2023Frontiers in immunologyFree full text
  18. JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17/Treg cells via regulating the JAK2/STAT3-AKT/mTOR signaling pathway.2023International immunopharmacology
  19. Preoperative respiratory muscle training combined with aerobic exercise improves respiratory vital capacity and daily life activity following surgical treatment for myasthenia gravis.2023Journal of cardiothoracic surgeryRCTFree full text
  20. An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
  21. Nomogram for the acute exacerbation of acetylcholine receptor antibody-positive generalized myasthenia gravis.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  22. Expression of Programmed Cell Death 1 Ligand 2 in Patients With Thymoma and Thymomatous Myasthenia Gravis.2022American journal of clinical pathology
  23. Is myasthenia gravis a contraindication for botulinum toxin?2022Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  24. Efficiency of ectopic thymectomy by three surgical approaches in non-thymomatous myasthenia gravis.2022Updates in surgeryFree full text
  25. Thymomatous myasthenia gravis: 10-year experience of a single center.2021Acta neurologica Scandinavica
  26. Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses.2021International immunopharmacology
  27. Factors affecting improvement of neurologic status evaluated by Quantitative Myasthenia Gravis Score for patients with thymomatous myasthenia gravis after extended thymectomy.2021Journal of translational medicineFree full text
  28. AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
Chinese-language papers (not in the count)1
  1. [To attach great importance to the identification of refractory myasthenia gravis].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status6
  1. Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia GravisStatus unknownNCT05332587Lead sponsorPhase 3Start 2020-08
  2. Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia GravisStatus unknownNCT03597373Lead sponsorStart 2017-01
  3. The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand ThymectomyCompletedNCT01727193Lead sponsorPhase 3Start 2012-09
  4. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  5. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Study sitePhase 3Start 2024-07
  6. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 4 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025

3 hospitals in Guangzhou for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRevascularisation surgeryImaging & blood flowGenetics
Departments in papersNeurologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 6 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 3.0%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 2220232024: 0020242025: 002025

5 hospitals in Guangzhou for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Brain & movement symptomsTreatment (chelation, zinc)
Departments in papersNeurologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 12 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 5.6%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 1120232024: 2220242025: 112025

2 hospitals in Guangzhou for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesScreening & diagnosisDisease mechanismsLong-term outcomes
Departments in papersPediatricsRadiology / nuclear medicine
Papers it led12
  1. Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.2025Hepatology (Baltimore, Md.)
  2. Interpretable artificial intelligence-based app assists inexperienced radiologists in diagnosing biliary atresia from sonographic gallbladder images.2024BMC medicineFree full text
  3. Mucosal-associated invariant T cells promote ductular reaction through amphiregulin in biliary atresia.2024EBioMedicineFree full text
  4. Percutaneous Ultrasound Cholangiography With Microbubbles in Children With Biliary Diseases.2023Ultrasound quarterly
  5. Gamma-Glutamyl Transferase Combined With Conventional Ultrasound Features in Diagnosing Biliary Atresia: A Two-Center Retrospective Analysis.2022Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  6. Percutaneous ultrasound-guided cholecystocholangiography with microbubbles combined with liver biopsy for the assessment of suspected biliary atresia.2022Pediatric radiology
  7. Postnatal outcomes of fetuses with isolated gallbladder anomalies: be aware of biliary atresia.2022The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  8. The Prognosis of Type III Biliary Atresia with Hilar Cyst.2021Indian journal of pediatrics
  9. Two-Dimensional Shear Wave Elastography Predicts Liver Fibrosis in Jaundiced Infants with Suspected Biliary Atresia: A Prospective Study.2021Korean journal of radiologyFree full text
  10. Ensembled deep learning model outperforms human experts in diagnosing biliary atresia from sonographic gallbladder images.2021Nature communicationsFree full text
  11. Ultrasound characteristics combined with gamma-glutamyl transpeptidase for diagnosis of biliary atresia in infants less than 30 days.2021Pediatric surgery international
  12. The combination of conventional ultrasound and shear-wave elastography in evaluating the segmental heterogeneity of liver fibrosis in biliary atresia patients after Kasai portoenterostomy.2021Pediatric surgery international
More papers found outside PubMed (not counted)1
  1. Folic acid prevents interferon-induced iron accumulation and ferroptosis and improves liver health in children with biliary atresia2023medRxivpreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

12 hospitals in Guangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Guangzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Guangzhou for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 9 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.9%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 4420232024: 2220242025: 112025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Over half of these papers are lab or animal studies.

Papers it led9
  1. ACSL4 Drives C5a/C5aR1-Calcium-Induced Fibroblast-to-Myofibroblast Transition in a Bleomycin-Induced Mouse Model of Pulmonary Fibrosis.2025Biomolecules
  2. Suppression of OGN in lung myofibroblasts attenuates pulmonary fibrosis by inhibiting integrin αv-mediated TGF-β/Smad pathway activation.2024Matrix biology : journal of the International Society for Matrix Biology
  3. YTHDC1 delays cellular senescence and pulmonary fibrosis by activating ATR in an m6A-independent manner.2024The EMBO journal
  4. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.2023BMC pulmonary medicine
  5. Identification of diagnostic hub genes related to neutrophils and infiltrating immune cell alterations in idiopathic pulmonary fibrosis.2023Frontiers in immunology
  6. DACT2 protects against pulmonary fibrosis via suppressing glycolysis in lung myofibroblasts.2023International journal of biological macromolecules
  7. Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway.2023Respiratory research
  8. Mesenchymal stromal cells attenuate alveolar type 2 cells senescence through regulating NAMPT-mediated NAD metabolism.2022Stem cell research & therapy
  9. Acute fibrinous and organizing pfneumonia: two case reports and literature review.2021Diagnostic pathology
All its trials on ClinicalTrials.gov, any status2
  1. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  2. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 4 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 7.3%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

2 hospitals in Guangzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePediatricsNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Guangzhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry DiseaseStatus unknownNCT06114329Study sitePhase 2Start 2023-10
  2. Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467Study siteStart 2021-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Guangzhou for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 5 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 2.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 0020232024: 1120242025: 002025

7 hospitals in Guangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led5
  1. Discordant Monozygotic Triplets with Duchenne Muscular Dystrophy.2024Annals of neurology
  2. Cardiac CIP protein regulates dystrophic cardiomyopathy.2022Molecular therapy : the journal of the American Society of Gene Therapy
  3. Serum creatinine as a biomarker for dystrophinopathy: a cross-sectional and longitudinal study.2021BMC neurology
  4. A rare case of monozygotic triplets with Duchenne muscular dystrophy.2021Neuromuscular disorders : NMD
  5. Generation and characterization of an induced pluripotent stem cell line (ZSYYDNi001-A) from a patient with Duchenne muscular dystrophy carrying exon 51 deletion in the DMD gene.2021Stem cell research
Earlier papers (2016–2020)6
  1. Engraftment of human induced pluripotent stem cell-derived myogenic progenitors restores dystrophin in mice with duchenne muscular dystrophy.2020Biological research
  2. Comprehensive analysis of the expression profile of circRNAs and their predicted protein-coding ability in the muscle of mdx mice.2020Functional & integrative genomics
  3. Synergistic effect of glucocorticoids and IGF-1 on myogenic differentiation through the Akt/GSK-3β pathway in C2C12 myoblasts.2020The International journal of neuroscience
  4. [Unexpected discovery of a fetus with DMD gene deletion using single nucleotide polymorphism array].2017Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  5. Diffusion-Tensor Imaging of Thigh Muscles in Duchenne Muscular Dystrophy: Correlation of Apparent Diffusion Coefficient and Fractional Anisotropy Values With Fatty Infiltration.2016AJR. American journal of roentgenology
  6. TGF-β1 activates the canonical NF-κB signaling to promote cell survival and proliferation in dystrophic muscle fibroblasts in vitro.2016Biochemical and biophysical research communications
All its trials on ClinicalTrials.gov, any status1
  1. Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDTerminatedNCT04632940Study sitePhase 3Start 2021-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 4 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 1.6%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

7 hospitals in Guangzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Guangzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical and pathological features and the misdiagnosis of childhood Alport syndrome: a retrospective analysis of 91 cases].2017Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromeActive, not recruitingNCT07211685Study sitePhase 2Start 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 22 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 3.0%.

Papers led
22
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 8820232024: 2220242025: 442025

20 hospitals in Guangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
    Phase
    Not given
    Started
    2016-11
    Registry
    NCT02954419

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  2. Recruiting
    IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
    Phase
    Not given
    Started
    2012-11
    Registry
    NCT03001947

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  3. Recruiting
    A Study of SHR-2173 in Participants With Primary IgA Nephropathy
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07354932

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  4. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

  5. Recruiting
    Correlation of Microbiome and Metabonomics With IgA Nephropathy
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05190848

    Age 16 years to 65 years (registered criteria)

    Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyRheumatology & immunologySurgery (general/hepatobiliary/pancreatic)
Papers it led22
  1. Machine learning-based unsupervised phenotypic clustering analysis of patients with IgA nephropathy: Distinct therapeutic responses of different groups.2026Chinese medical journal
  2. Left ventricular remodeling in IgA nephropathy: Prognostic implications and clinical correlations.2026European journal of internal medicine
  3. Clinicopathological Characteristics and Prognosis of IgA Nephropathy Combined With Malignant Hypertension Kidney Injury.2025Journal of clinical laboratory analysis
  4. Single-cell transcriptomics reveals the immune mechanisms by which tonsillectomy improves clinical outcomes of recurrent Immuoglobulin A nephropathy after kidney transplant.2025Molecular immunology
  5. Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy.2025Renal failure
  6. Clinical features, pathological characteristics, and prognosis of patients with IgA nephropathy complicated with nephrotic syndrome.2025Scientific reports
  7. Differences of clinicopathological characteristics and outcomes of IgA nephropathy patients with and without nephrotic syndrome.2024International urology and nephrology
  8. Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study.2024Nephrology (Carlton, Vic.)
  9. Clinicopathological Features and Outcomes of IgA Nephropathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity.2023American journal of nephrology
  10. Does inflammatory bowel disease promote kidney diseases: a mendelian randomization study with populations of European ancestry.2023BMC medical genomics
  11. Prognostic significance of the extent of tubulointerstitial lesions in patients with IgA nephropathy.2023International urology and nephrology
  12. RhoA vesicle trafficking-mediated transglutaminase 2 membrane translocation promotes IgA1 mesangial deposition in IgA nephropathy.2023JCI insight
  13. Polymorphisms of CARD9 Gene Predict Disease Progression and Renal Survival of Immunoglobulin A Nephropathy.2023Kidney & blood pressure research
  14. Hyperuricemia is associated with the progression of IgA nephropathy in children.2023Pediatric research
  15. Comparative analysis between the safety and efficacy of oral corticosteroids versus corticosteroids pulse therapies in IgA nephropathy.2023Renal failure
  16. Mitochondrial DNA copy number in peripheral blood of IgA nephropathy: a cross-sectional study.2023Renal failure
  17. Functional variant rs12614 in CFB confers a low risk of IgA nephropathy by attenuating complement alternative pathway activation in Han Chinese.2022Frontiers in immunology
  18. Dyslipidemia may be a risk factor for progression in children with IgA nephropathy.2022Pediatric nephrology (Berlin, Germany)
  19. Color Doppler Ultrasound and Hemodynamics for Evaluating Graft Dysfunction in Recurrent Immunoglobulin A Nephropathy.2021Annals of transplantation
  20. Clinicopathological characteristics and prognosis of patients with IgA nephropathy and renal vasculitic lesions.2021BMC nephrology
  21. Epigenome-wide association study and network analysis for IgA Nephropathy from CD19+ B-cell in Chinese Population.2021Epigenetics
  22. Expression profile of Fc receptor-like molecules in patients with IgA nephropathy.2021Human immunology
Earlier papers (2016–2020)27
  1. Upregulated Expression of Intestinal Antimicrobial Peptide HD5 Associated with Renal Function in IgA Nephropathy.2020Disease markers
  2. ST6GAL1 polymorphisms influence susceptibility and progression of IgA nephropathy in a Chinese Han population.2020Immunobiology
  3. TLR7 in B cells promotes renal inflammation and Gd-IgA1 synthesis in IgA nephropathy.2020JCI insight
  4. Identification of susceptibility locus shared by IgA nephropathy and inflammatory bowel disease in a Chinese Han population.2020Journal of human genetics
  5. Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci and Reveals Ethnic Heterogeneity of Genetic Susceptibility for IgA Nephropathy.2020Journal of the American Society of Nephrology : JASN
  6. Clinical, pathological characteristics and outcomes of immunoglobulin A nephropathy patients with different ages.2020Nephrology (Carlton, Vic.)
  7. [Therapeutic effect of tonsillectomy on IgA nephropathy after kidney transplantation].2020Zhonghua yi xue za zhi
  8. Graft failure of IgA nephropathy in renal allografts following living donor transplantation: predictive factor analysis of 102 biopsies.2019BMC nephrology
  9. Association of FCRL3 Gene Polymorphisms with IgA Nephropathy in a Chinese Han Population.2019DNA and cell biology
  10. Association of ITGAX and ITGAM gene polymorphisms with susceptibility to IgA nephropathy.2019Journal of human genetics
  11. Concurrent Kidney Glomerular and Interstitial Lesions Associated with Kimura's Disease.2019Nephron
  12. Gender-related differences in clinicopathological characteristics and renal outcomes of Chinese patients with IgA nephropathy.2018BMC nephrology
  13. A proposed Oxford classification-based clinicopathological nomogram for predicting short-term renal outcomes in IgA nephropathy after acute kidney injury.2018European journal of internal medicine
  14. Genetic study of immunoglobulin A nephropathy: From research to clinical application.2018Nephrology (Carlton, Vic.)
  15. Genetic Determinants of IgA Nephropathy: Eastern Perspective.2018Seminars in nephrology
  16. Higher Incidence of Renal Allograft Glomerulonephritis in Living-Related Donor Kidney Transplantation.2018Transplantation proceedings
  17. The mTOR/p70S6K1 signaling pathway in renal fibrosis of children with immunoglobulin A nephropathy.2017Journal of the renin-angiotensin-aldosterone system : JRAAS
  18. Increased Abundance of Plasmacytoid Dendritic Cells and Interferon-Alpha Induces Plasma Cell Differentiation in Patients of IgA Nephropathy.2017Mediators of inflammation
  19. Clinical outcomes of IgA nephropathy patients with different proportions of crescents.2017Medicine
  20. Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: Correlation with clinical features and Streptococcus pyogenes infection.2017Molecular medicine reports
  21. Association of TNFSF13 polymorphisms with IgA nephropathy in a Chinese Han population.2017The journal of gene medicine
  22. DQB1*060101 may contribute to susceptibility to immunoglobulin A nephropathy in southern Han Chinese.2016Frontiers of medicine
  23. Vitamin D-Binding Protein Is a Potential Urinary Biomarker of Irbesartan Treatment Response in Patients with IgA Nephropathy.2016Genetic testing and molecular biomarkers
  24. Plasma oxidative stress level of IgA nephropathy in children and the effect of early intervention with angiotensin-converting enzyme inhibitors.2016Journal of the renin-angiotensin-aldosterone system : JRAAS
  25. Twenty-eight-year review of childhood renal diseases from renal biopsy data: A single centre in China.2016Nephrology (Carlton, Vic.)
  26. Clinicopathological features and risk factors analysis of IgA nephropathy associated with acute kidney injury.2016Renal failure
  27. Low α-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction.2016Science translational medicine
All its trials on ClinicalTrials.gov, any status8
  1. IgA Nephropathy Biomarkers Evaluation Study (INTEREST)RecruitingNCT02954419Lead (inferred)Start 2016-11
  2. IgA Nephropathy Registration Initiative of High Quality (INSIGHT)RecruitingNCT03001947Lead (inferred)Start 2012-11
  3. Effect of Tonsillectomy on Longterm Renal Outcome of IgA NephropathySuspendedNCT02471599Lead (inferred)N/AStart 2011-03
  4. A Study of SHR-2173 in Participants With Primary IgA NephropathyRecruitingNCT07354932Study sitePhase 2Start 2026-03
  5. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  6. Correlation of Microbiome and Metabonomics With IgA NephropathyRecruitingNCT05190848Study siteStart 2020-05
  7. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  8. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Guangzhou for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Guangzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Guangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Guangzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Guangzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Current status of hereditary gastrointestinal neoplasms].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中山大学附属第一医院

First Affiliated Hospital of Sun Yat-sen University

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First Affiliated Hospital of Sun Yat-Sen University; Sun Yat-sen University First Affiliated Hospital; Hui Ya Hospital of The First Affiliated Hospital; Affiliated Hospital of Guangdong Public Institution of Medicine; First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University; Zhongshan Hospital

Suggest a correctionDownload the data